Thor Medical releases updated investor presentation
11.6.2024 08:00:01 CEST | Thor Medical ASA | Non-regulatory press releases

Oslo, Norway, 11 June 2024: Thor Medical has prepared updated presentation
material in connection with upcoming investor meetings, including a status
update on the company's evaluation of a fast-track plant to enable delivery of
commercial volumes of Th-228 by end of 2025. The enclosed presentation is also
available on the company's website.

Several radiopharmaceutical companies are in clinical trials with products based
on the decay of parent isotope Th-228, and several more are expected to commence
trials over the years to come. Thor Medical's customers among these companies
are requesting commercial volumes of high-purity Th-228 as soon as possible.
Demand from clinical trials alone is expected to generate a market for Th-228 of
around USD 100 million over the next few years.

Thor Medical is currently building a pilot plant to verify its production
technology in industrial scale and produce customer samples for qualification.
Building on this, and in response to the outlined demand, the company has
initiated a feasibility study for a fast-track plant to deliver commercial
volumes of Th-228 already by end of next year.

Launches of approved radiopharmaceutical end-products for cancer treatment going
forward are expected to increase the global market for Th-228 up to USD 1
billion by 2032.

For more details, please see the updated investor presentation.

CONTACTS

* Brede Ellingsæter, CFO, Thor Medical ASA, +47 472 38 440,
brede.ellingseter@thormedical.no